Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
EFBI Eagle Financial Bancorp Inc
CNSP CNS Pharmaceuticals Inc
DIDIY DiDi Global Inc
QLGN Qualigen Therapeutics Inc
JOFF JOFF Fintech Acquisition Corp
IR Ingersoll Rand Inc
TGT Target Corp
CCLP CSI Compressco LP
BIOT Biotech Acquisition Co
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Postmarket

Last Trade
Delayed
$200.01
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$200.01
Day's Change
-0.78 (-0.39%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
204.40
Day's Low
199.21
Volume
(Above Average)
Volume:
356,348

10-day average volume:
312,745
356,348

Company Profile

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
163.02x
Price/Book (MRQ)
5.82x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
1.7M
Previous Month
1.6M
Percent of Float
5.34%
Days to Cover
5.0564 Days

Share Information

KRTX is in a share class of common stock
Float
32.4M
Shares Outstanding
34.4M
Institutions Holding Shares
325
98.37%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Steven M. PaulDir.
  • Troy A. IgnelziCFO
  • Andrew Craig MillerCOO
  • Stephen BrannanOther
  • Charmaine LykinsOther

Address

Insider Trading

During the most recent quarter, 120K shares were bought, and 156K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.